Cookies

Like most websites The Pathologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Diagnostics Oncology, Precision medicine, Screening and monitoring, Regulation and standards, Genetics and epigenetics, Omics

How to HER2

Gastroesophageal adenocarcinoma (GEA) is consistently in the top five cancers globally, with over 43,000 cancer cases this year in the United States alone, and yet, in spite of this high prevalence, it still goes largely undiagnosed until the late stages. HER2-targeted therapies, best known for their role in breast cancer treatment, can offer some hope – but delayed diagnosis limits their effectiveness (1). In the absence of any clear guidance, and the insufficiency of HER2 testing guidance for breast cancer in this set of patients, the College of American Pathologists, the American Society for Clinical Pathology, and the American Society of Clinical Oncology teamed up to issue joint evidence-based guidelines for HER2 testing in GEA (1).

Table 1. CAP/ASCP/ASCO guidelines to pathologists for HER2 testing in GEA patients.

The expert panel created a list of 11 recommendations to ensure optimal HER2 testing – three specifically aimed at clinicians and eight at pathologists. Those for pathologists are listed in Table 1.

According to guideline Co-chair, Mary Kay Washington, a pathologist at Vanderbilt University Medical Center, “The pathologist can use the guidelines to decide which specimens might be best suited for testing,” adding, “it also provides a step-by-step procedure for the order in which the tests should be performed.” Given the high prevalence of the condition, Washington believes “this guideline has the potential to impact a large number of patients.”

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. AN Bartley et al., “HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathologists, and American Society of Clinical Oncology”, Arch Pathol Lab Med, 140, 1345-1363 (2016). PMID: 27841667.
About the Author
William Aryitey

My fascination with science, gaming, and writing led to my studying biology at university, while simultaneously working as an online games journalist. After university, I travelled across Europe, working on a novel and developing a game, before finding my way to Texere. As Associate Editor, I’m evolving my loves of science and writing, while continuing to pursue my passion for gaming and creative writing in a personal capacity.

Related Application Notes
Superior Determination of HPV using RNAscope™ In Situ Hybridization

| Contributed by Bio-Techne

Biomarker Optimization on LabSat® Research

| Contributed by Lunaphore Technologies

Diagnostics Genetics and epigenetics
A single NGS workflow for comprehensive genomic profiling

| Contributed by QIAGEN

Related Product Profile
Diagnostics Genetics and epigenetics
QIAseq® Pan Cancer Multimodal cuts user interventions by 50%

| Contributed by QIAGEN

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register